David McAllister
Overview
Explore the profile of David McAllister including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
942
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McChrystal R, Lees J, Gillies K, McAllister D, Hanlon P
Trials
. 2025 Mar;
26(1):84.
PMID: 40075486
Background: Trial attrition poses several risks for the validity of randomised controlled trials (RCTs). To better understand attrition, studies have explored and identified predictors among participant and trial characteristics. Reviews...
2.
Hudson J, Sanga L, Jobe M, Etyang A, McAllister D, Perel P, et al.
JACC Adv
. 2025 Jan;
3(12):101383.
PMID: 39817086
Background: There is a growing burden of acute coronary syndrome (ACS) and heart failure (HF) in sub-Saharan Africa (SSA), yet outcomes remain poor compared to high-income countries. The European Society...
3.
Sun Y, Witham M, Clegg A, Taylor R, Dibben G, McAllister D, et al.
Age Ageing
. 2024 Nov;
53(11).
PMID: 39572393
Background: Frailty is of increasing interest in trials, either as a target of intervention, as an outcome or as a potential treatment modifier. However, frailty measurement is often highly variable....
4.
Wei L, Butterly E, Rodriguez Perez J, Chowdhury A, Shemilt R, Hanlon P, et al.
BMJ Open
. 2024 Jun;
14(6):e081315.
PMID: 38908852
Introduction: In trials, subgroup analyses are used to examine whether treatment effects differ by important patient characteristics. However, which subgroups are most commonly reported has not been comprehensively described. Design...
5.
McGurnaghan S, McKeigue P, Blackbourn L, Mellor J, Caparrotta T, Sattar N, et al.
Diabetes Care
. 2024 Jun;
47(8):1342-1349.
PMID: 38889071
Objective: In this study we examine whether hospitalized coronavirus disease 2019 (COVID-19) pneumonia increases long-term cardiovascular mortality more than other hospitalized pneumonias in people with type 2 diabetes and aim...
6.
Deo S, Al-Kindi S, Motairek I, McAllister D, Shah A, Elgudin Y, et al.
Circ Cardiovasc Qual Outcomes
. 2024 Feb;
17(3):e010166.
PMID: 38328913
Background: Patients with type 2 diabetes are at risk of heart failure hospitalization. As social determinants of health are rarely included in risk models, we validated and recalibrated the WATCH-DM...
7.
Hanlon P, Morrison H, Morton F, Jani B, Siebert S, Lewsey J, et al.
Wellcome Open Res
. 2023 Sep;
6:244.
PMID: 37746318
Frailty, an age-related decline in physiological reserve, is an increasingly important concept in the management of chronic diseases. The implications of frailty in people with rheumatoid arthritis are not well...
8.
MacRae C, Morales D, Mercer S, Lone N, Lawson A, Jefferson E, et al.
BMC Med
. 2023 Aug;
21(1):309.
PMID: 37582755
Background: Measurement of multimorbidity in research is variable, including the choice of the data source used to ascertain conditions. We compared the estimated prevalence of multimorbidity and associations with mortality...
9.
Hanlon P, McAllister D, Wild S, Mair F, Guthrie B, Butterly E, et al.
Ann Fam Med
. 2023 Mar;
(21 Suppl 1).
PMID: 36972531
Context: The applicability of randomised controlled trials of pharmacological agents to older people with frailty/multimorbidity is often uncertain, due to concerns that trials are not representative. However, assessing trial representativeness...
10.
Deo S, McAllister D, LaForest S, Altarabsheh S, Elgudin Y, Dunlay S, et al.
Am J Cardiovasc Drugs
. 2023 Mar;
23(3):311-321.
PMID: 36947397
Background: Effective lipid lowering is essential in patients with peripheral arterial disease (PAD) and cerebrovascular disease (CeVD). Proprotein convertase subtilsin/kexin type 9 inhibitors (PCSK9i) efficiently lower low-density lipoprotein (LDL) levels;...